Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
AI Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
AI Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
drug safety
Pharma
FDA orders GLP-1s add eye risk to labels
The FDA is ordering drugmakers to add a new and rare eye risk to the labels of 12 GLP-1s, including Zepbound and Ozempic.
Donavyn Coffey
Nov 10, 2026 8:31am
FDA probes Novartis’ Zolgensma gene therapy over cancer risks
Nov 9, 2026 11:14am
Novartis confirms several new tumor cases in Zolgensma patients
Nov 6, 2026 9:59am
Ex-Madrigal clinical head files Rezdiffra whistleblower suit
Nov 4, 2026 10:49am
Kennedy eases up enforcement on compounding of 6 peptides
Oct 29, 2026 8:12am
Proposed nuclear rules threaten Novartis’ Pluvicto
Oct 6, 2026 9:00am
